TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03915223

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: leg fracture
Description: Surgical leg fracture with injection of solumedrol (steroidal anti-inflammatory drug) or physiological serum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leg fracture
Description: Surgical leg fracture with injection of solumedrol (steroidal anti-inflammatory drug) or physiological serum
Study: NCT02918773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone otoscope
Description: A smartphone otoscope is a pocket size smartphone attachment that uses the technology and light source of a smartphone to capture reproducible images of the ear canal and tympanic membrane. The smartphone otoscope has the capability to capture still images and video, which can be referred to post-examination as well as be incorporated into an electronic medical record. Clinicians will use the smartphone otoscope for the duration of the 6-month study period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional otoscope
Description: A conventional otoscope has a light and lenses to provide a view of the ear canal and tympanic membrane or eardrum. Clinicians will use the conventional otoscope for the duration of the 6-month study period.
Study: NCT03934450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPQ
Description: The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPQ
Description: The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine Phosphate
Description: The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
Study: NCT02891304

Intervention type: OTHER
Intervention: Quarterly Feedback
Description: Learning curves received quarterly vs. annually
Study: NCT04344587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-prone position recommendation
Description: The Qualtrics self-prone position recommendation intervention website will include the following sections:~1. Welcome message~2. Educational review of the potential benefits of prone positioning~3. How-To guide to safely prone in a hospital bed~4. A recommendation to prone while lying in bed (4 times for 1-2 hours each during the day and at night every 24 hours).~5. A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The Qualtrics usual care website will include the following sections:~1. Welcome message~2. A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking
Study: NCT01355939

Intervention type: PROCEDURE
Intervention: Clinically-Indicated Abdominal Re-Exploration Surgery
Description: This is a prospective observational study. Abdominal re-exploration surgery is clinically-indicated and planned as the standard of care for the patients regardless of their decision to participate in the study.

Intervention type: PROCEDURE
Intervention: Clinically-Indicated Abdominal Re-Exploration Surgery
Description: This is a prospective observational study. Abdominal re-exploration surgery is clinically-indicated and planned as the standard of care for the patients regardless of their decision to participate in the study.

Intervention type: PROCEDURE
Intervention: Clinically-Indicated Abdominal Re-Exploration Surgery
Description: This is a prospective observational study. Abdominal re-exploration surgery is clinically-indicated and planned as the standard of care for the patients regardless of their decision to participate in the study.
Study: NCT04435600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Subcutaneous Injection
Study: NCT04077437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Standardized non-directive therapy performed by therapist team.
Study: NCT01355939

Intervention type: PROCEDURE
Intervention: Clinically-Indicated Abdominal Re-Exploration Surgery
Description: This is a prospective observational study. Abdominal re-exploration surgery is clinically-indicated and planned as the standard of care for the patients regardless of their decision to participate in the study.
Study: NCT01073566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Finesse
Description: Finesse Insulin Delivery Patch

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pen/Syringe (Usual injection device)
Description: Pen/Syringe
Study: NCT04077437

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapy
Description: Standardized non-directive therapy performed by therapist team.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine
Description: Administration of 80 to 120 mg midomafetamine HCl, followed by a supplemental half-dose 1.5 to 2 hrs after the initial dose of 40 or 60 mg, respectively, during three sessions of MDMA-assisted psychotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo with therapy during three experimental sessions
Study: NCT03671213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calypso Knee System (Implantable Shock Absorber)
Description: The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
Study: NCT03466411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 1
Description: Guselkumab will be administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 2
Description: Guselkumab will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 2
Description: Guselkumab will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 3
Description: Guselkumab will be administered by IV infusion.
Study: NCT04623450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoothie
Description: Preload smoothies that are matched for taste, smell, appearance, quantity and calorie but different caloric content.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoothie
Description: Preload smoothies that are matched for taste, smell, appearance, quantity and calorie but different caloric content.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoothie
Description: Preload smoothies that are matched for taste, smell, appearance, quantity and calorie but different caloric content.
Study: NCT01968135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptive Pill
Description: 150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sugar Pill
Description: Placebo Sugar Pill
Study: NCT02917889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Volunteers will consume 300 mg of caffeine in pills fifteen minutes before treadmill aerobic exercise.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Volunteers will consume 300 mg of placebo in pills fifteen minutes before treadmill aerobic exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary test
Description: assessment of the maximum oxygen consumption (VO2max) on a treadmill (Inbrasport / Millennium), using Buce protocol.~.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary test
Description: assessment of the maximum oxygen consumption (VO2max) on a treadmill (Inbrasport / Millennium), using Buce protocol.~.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill aerobic exercise
Description: 30 mim of aerobic exercise (5 minutes at speed of 5.0 km/h for warming-up followed by 25 minutes at 60% of VO2max ).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill aerobic exercise
Description: 30 mim of aerobic exercise (5 minutes at speed of 5.0 km/h for warming-up followed by 25 minutes at 60% of VO2max ).
Study: NCT03449823

Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler ultrasound of fetal renal artery
Description: Doppler ultrasound assessment of the proximal fetal renal artery to with measurement of the peak systolic velocity, resistive index, pulsatility index, and systolic/diastolic ratio.

Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler ultrasound of fetal renal artery
Description: Doppler ultrasound assessment of the proximal fetal renal artery to with measurement of the peak systolic velocity, resistive index, pulsatility index, and systolic/diastolic ratio.
Study: NCT03041285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idronoxil (NOX66) suppository
Description: Patients in Group 1 will be given 400mg of Idronoxil suppository (NOX66) (1 suppository) daily from Day 0(1 day before radiotherapy) until 7 days after radiotherapy. Group 2 will be given Idronoxil (NOX66) 800mg (2 suppositories) daily from Day 0 until 7 days after radiotherapy.~All patients will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 fractions.~Radiotherapy session will involve irradiation of 1-2 lesions.~.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idronoxil (NOX66) suppository
Description: Patients in Group 1 will be given 400mg of Idronoxil suppository (NOX66) (1 suppository) daily from Day 0(1 day before radiotherapy) until 7 days after radiotherapy. Group 2 will be given Idronoxil (NOX66) 800mg (2 suppositories) daily from Day 0 until 7 days after radiotherapy.~All patients will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 fractions.~Radiotherapy session will involve irradiation of 1-2 lesions.~.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: All patients (Group 1 and Group 2) will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 daily fractions on consecutive days. Radiotherapy session (week 1) will involve irradiation to 1-2 lesions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: All patients (Group 1 and Group 2) will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 daily fractions on consecutive days. Radiotherapy session (week 1) will involve irradiation to 1-2 lesions.
Study: NCT01357486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: patients receiving sorafenib 400 mg - twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: patients receiving pravastatin 40 mg - once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib + Pravastatin
Description: patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)

Intervention type: OTHER
Group type: OTHER
Intervention: patients receiving best supportive care
Description: palliative management
Study: NCT01936545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol during liver transplantation.
Description: The anesthesia was maintained with propofol during liver transplantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane during liver transplantation.
Description: The anesthesia was maintained with desflurane during liver transplantation.
Study: NCT00003460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Children with a primitive neuroectodermal tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT00575809

Intervention type: OTHER
Intervention: Mucositis and nutritional assessments
Description: Mucositis and nutritional assessments before and during the hematopoietic stem cell transplantation
Study: NCT00209378

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regional anticoagulation with citrate
Description: Regional anticoagulation with trisodium citrate is compared with standard systemic heparinization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HfCitPre
Description: regional anticoagulation with citrate containing replacement solution
Study: NCT00267748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate Continuous Daily Dosing
Description: Sunitinib malate starting dose 37.5 mg daily continuous daily regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate Schedule 4/2
Description: Sunitinib malate starting dose 50 mg per day for four weeks, followed by a two week off-drug period. This six week cycle is repeated.
Study: NCT02535533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenomethionine (SLM)
Description: SLM administrated orally twice daily for 14 days followed by SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Following SLM administrated orally twice daily for 14 days, SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenomethionine (SLM)
Description: Maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 (4000 mcg SLM) given orally twice daily for 14 days, followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Following maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 (4000 mcg SLM) given orally twice daily for 14 days, SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenomethionine (SLM)
Description: Pilot Phase - Dosing will begin at dose level 3 (4000, 5000 or 6000 mcg SLM calculated based on patients' BSA). SLM will be given orally twice daily for 14 days
Study: NCT00381771

Intervention type: BEHAVIORAL
Intervention: Conservative management for xerostomia
Description: Active hydration (drinking more than 10 cups of water per day), Humidification, Oral gargle with a diluted (0.05% to 0.1%) chlorhexidine solution, Sugarless chewing gum, Saliva-stimulating sour juice (sugarless orange juice), Commercial artificial saliva, Nasal saline spray 3 to 4 times a day, Warm massage of the 4 major salivary glands.
Study: NCT02213809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case method education in COPD
Description: In case method a rich narrative describing of a real-life situation (teaching case) is presented, in which the learning group must make a decision or solve a problem. The teaching case provide information, but neither analysis nor conclusions. The analytical work of explaining the relationships among events in the case, identifying options, evaluating choices and predicting the effects of actions is the work done by students during the discussion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional education in COPD
Description: Traditional education in this study means that the teacher mainly speaks to the group. Although short cases may be used for illustration, the main focus is not that the group shall solve problems from a narrative case.
Study: NCT03432078

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotherapy
Description: Non-pharmacological treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotherapy
Description: Non-pharmacological treatment
Study: NCT01784861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-82

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-82

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-82

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-82

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-82

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-82

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study: NCT02122237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cefaly tDCS
Description: Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular cathodal tDCS decreases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
Study: NCT03648697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-TCR-T (YT-E001) cells
Description: EBV-TCR-T (YT-E001) cells are prepared via lentiviral infection. 6-10 days prior to infusion of TCR-T cells (YT-E001), subjects receive fludarabine at dose 30mg/m2/day for 4 days and cyclophosphamide treatment at dose 30mg/kg/day for 2 days and take a rest for one day before infusion.~Patients, who receive an infusion of YT-E001, will remain in the hospital to be monitored for adverse events until they have recovered from the treatment. Patients will have frequent follow-up visit to monitor the persistence of modified T cells and efficacy of the treatment.
Study: NCT02498626

Intervention type: OTHER
Intervention: venous saturations
Description: Samples of venous saturations from the central venous line (CVP), from venous side of the heart lung machine and from the pulmonary artery were taken at 10 min after being on CPB and after correction of the cardiac defects.
Study: NCT02630758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Yoga
Description: See study arm description.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking Control Condition
Description: See study arm description.
Study: NCT01415427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110 - Weekly
Description: In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/qw administered over a period of approximately 4 hours once a week.~In Part 2, patients will continue to receive 2.0 mg/kg of BMN 110 every week, with no placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110 - Every Other Week
Description: In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week. Patients randomized to the 2.0 mg/kg/qow arm will receive infusions of placebo on alternating weeks, to mask active drug weeks.~In Part 2, patients will receive 2.0 mg/kg of BMN 110 every week, with no placebo.
Study: NCT04064775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart snacking intervention
Description: The smart snacking intervention aimed to examine whether peer-led nudging on social media influenced adolescents to reduce their self-reported ideal portion sizes for a variety of HED snacks and SSBs. In intervention 2, participants were randomly allocated to the intervention or control condition, and their ideal portion sizes were assessed through a survey at baseline and intervention end.
Study: NCT03246737

Intervention type: OTHER
Intervention: monitoring
Study: NCT02569762

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose-Aspartame
Description: Sucralose or aspartame

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose-Aspartame
Description: Sucralose or aspartame

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aspartame-Sucralose
Description: Aspartame or sucralose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aspartame-Sucralose
Description: Aspartame or sucralose
Study: NCT01297270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI201335
Description: QD BI 201335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIFN/RBV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI201335
Description: QD (once daily) BI 201335

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04049045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 mg
Description: Empagliflozin 25 mg film-coated tablets, for oral use administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching Placebo, film-coated tablets, for oral use, matching to investigational product Jardiance® administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
Study: NCT04004884

Intervention type: DRUG
Intervention: Ulipristal Acetate
Description: Assess the variations of liver blood test parameters during UPA treatment for symptomatic uterine fibroids
Study: NCT03995615

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planing
Description: * After initial clinical evaluation, supra gingival calculus removal will be done. GCF samples will be collected from the control and test groups (Baseline samples) using paper strips (ORAFLOW). ® Group III patients will undergo a through oral hygiene instructions, full mouth supra-gingival and sub- gingival scaling and root planing clinical parameters will be re-recorded 6 weeks later and a 2nd GCF samples will be collected from selected test site from each patients following periodontal intervention.~* All the samples will be placed in eppendorf vials containing the buffer solution and samples will be stored at -800 c until the time of analysis by Enzyme -linked immune sorbent assay kit (ELISA) (GENX BIO) TM